|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2200062406 |
|
最近更新日期: Date of Last Refreshed on: |
2022-08-04 21:12:36 |
|
注册时间: Date of Registration: |
2022-08-04 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
外阴上皮内非瘤样病变发病相关的氨基酸及脂质组学分析 |
|
Public title: |
Analysis of amino acids and lipidomics associated with the pathogenesis of vulvar intraepithelial non-neoplastic lesions |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
外阴上皮内非瘤样病变发病相关的氨基酸及脂质组学分析 |
|
Scientific title: |
Analysis of amino acids and lipidomics associated with the pathogenesis of vulvar intraepithelial non-neoplastic lesions |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
何添 |
研究负责人: |
常淑芳 |
|
Applicant: |
He Tian |
Study leader: |
Shufang Chang |
|
申请注册联系人电话: Applicant telephone: |
15025382230 |
研究负责人电话:
Study leader's |
15902304934 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
1102259359@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
shfch2005@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
1102259359@qq.com |
研究负责人通讯地址: |
shfch2005@163.com |
|
Applicant address: |
1102259359@qq.com |
Study leader's address: |
shfch2005@163.com |
|
申请注册联系人邮政编码: Applicant postcode: |
400010 |
研究负责人邮政编码: Study leader's postcode: |
400010 |
|
申请人所在单位: |
重庆医科大学附属第二医院 |
||
|
Applicant's institution: |
The Second Affiliated Hospital of Chongqing Medical University |
||
|
研究负责人所在单位: |
重庆医科大学附属第二医院 |
||
|
Affiliation of the Leader: |
The Second Affiliated Hospital of Chongqing Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2021年科伦审第(72)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
重庆医科大学附属第二医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of the Second Affiliated Hospital of Chongqing Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2021-08-26 00:00:00 | ||
|
伦理委员会联系人: |
王大刚、任红、邓忠良 |
||
|
Contact Name of the ethic committee: |
Dagang Wang |
||
|
伦理委员会联系地址: |
重庆市渝中区临江路76号 |
||
|
Contact Address of the ethic committee: |
No. 76 Linjiang Road, Yuzhong District, Chongqing |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
常淑芬 |
||||||||||||||||||||||
|
Primary sponsor: |
Shufang Chang |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
重庆市渝中区临江路76号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 76 Linjiang Road, Yuzhong District, Chongqing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
重庆医科大学附属第二医院 |
||||||||||||||||||||||
|
Source(s) of funding: |
The Second Affiliated Hospital of Chongqing Medical University |
||||||||||||||||||||||
|
研究疾病: |
外阴上皮内非瘤样病变 |
||||||||||||||||||||||
|
Target disease: |
Vulvar intraepithelial nonneoplastic lesions |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
病因学/相关因素研究 |
||||||||||||||||||||||
|
Study type: |
Cause/Relative factors study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
病例研究 |
||||||||||||||||||||||
|
Study design: |
Case study |
||||||||||||||||||||||
|
研究目的: |
本课题拟在通过检测异常皮肤与临近皮肤之间氨基酸及脂质的代谢情况,探究与疾病色素减退、皮肤弹性减退的相关性。 |
||||||||||||||||||||||
|
Objectives of Study: |
This project intends to explore the correlation with disease hypopigmentation and skin elasticity by detecting the metabolism of amino acids and lipids between abnormal skin and adjacent skin. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1) 年龄在18-60岁;2)选择已经临床或病理确诊为外阴硬化性苔藓或外阴慢性单纯型苔藓;2)没有证据表明使用了包括免疫抑制药物、化疗、抗炎药物、抗组胺药或类固醇在内的药物,或有活动性外阴/阴道感染或高血压/心血管疾病的迹象;3)有意愿参加本次研究,签署知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
1) Aged 18-60 years old; 2) Choose to have clinical or pathological diagnosis of vulvar lichen sclerosus or vulvar lichen simplex; 2) There is no evidence of the use of immunosuppressive drugs, chemotherapy, anti-inflammatory drugs, antihistamines Drugs or steroids, or have signs of active vulvar/vaginal infection or hypertension/cardiovascular disease; 3) Willing to participate in this study and sign informed consent. |
||||||||||||||||||||||
|
排除标准: |
1) 活检结果提示外阴癌或外阴上皮内瘤变者;2) 急性或活动性外阴/阴道感染或高血压/心血管疾病者;3) 妊娠期、哺乳期及月经期妇女; 4)活检前3个月内有物理治疗或糖皮质激素类药物治疗史,3个月内使用了包括免疫抑制药物、化疗、抗炎药物、抗组胺药或类固醇在内的药物,;5)严重基础疾病不能配合或耐受治疗。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1) Biopsy results suggest vulvar cancer or vulvar intraepithelial neoplasia; 2) Acute or active vulvar/vaginal infection or hypertension/cardiovascular disease; 3) Pregnant, lactating and menstrual women; 4) Before biopsy History of physical therapy or glucocorticoid therapy within 3 months, use of drugs including immunosuppressive drugs, chemotherapy, anti-inflammatory drugs, antihistamines or steroids within 3 months; 5) Severe underlying diseases Inability to cooperate or tolerate treatment. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2022-08-01 00:00:00至 To 2022-12-15 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2022-08-01 00:00:00 至 To 2022-12-15 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
将患者按照外阴慢性单纯性苔藓和外阴硬化性苔藓分为两类,然后再每种类型中随机抽取样本单位 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Patients were divided into two categories according to vulvar lichen simplex and vulvar lichen sclerosus, and then randomly selected sample units from each type |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
2023-6-1,临床试验公共管理平台 www.medresman.org.cn |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
2023-6-1,Clinical trial public management platform,www.medresman.org.cn |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
临床试验公共管理平台ResMan |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Clinical trial public management platform(ResMan) |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |